Clinical trials: Pathologic Neovascularization
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Corneal Neovascularization
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing corneal transplantation.
- Trial name
- NCT00769145
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Miami
Age-related Macular Degeneration
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
- Trial name
- CAPTAIN (NCT00500344)
- Testing
- Lucentis (ranibizumab)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Neovascular Age-Related Macular Degeneration
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging.
- Trial name
- NCT00344227
- Testing
- Lucentis (Ranibizumab)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Age-Related Macular Degeneration
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related…
- Trial name
- NCT05984927
- Testing
- NG101 AAV gene therapy
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Elisigen, Inc.
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to causes other than age related macular degeneration…
- Trial name
- NCT01628354
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- University of Melbourne
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Type 2 Diabetes Mellitus
Orthogonal Polarisation Study in Young, Elderly and Type 2 Diabetics
Aging is accompanied by a progressive loss of skeletal muscle mass and strength, leading to the loss of functional capacity and an increased risk of developing chronic metabolic disease.
- Trial name
- NCT01476384
- Testing
- Glucose
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Angiogenesis, Ischemic Stroke
Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits
Neovascularization Induced by Mechanical Barrier disrUption and Systemic erythropoietin in patients with cerebral perfusion deficits (NIMBUS trial)
- Trial name
- NIMBUS (NCT02603406)
- Testing
- erythropoietin
- Volunteers
- 44 people
- Sponsor
- Ajou University School of Medicine
Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
- Trial name
- PALLAS (NCT07389980)
- Testing
- aflibercept 8 mg
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Coronary Artery Disease, Vascularization
Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery
Heart disease is the leading cause of death globally, accounting for 16% of the world's total deaths. The number of cases is expected to increase as our population ages. Heart disease also results in large economic burden.
- Trial name
- ACT for CABG (NCT06207318)
- Testing
- Acceptance and commitment therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Iowa
Choroidal Neovascularization
TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration
The purpose of the study is to compare photodynamic therapy to transpupillary thermotherapy as a treatment method for choroidal neovascularization in age-related macular degeneration ( AMD).
- Trial name
- NCT00260403
- Testing
- Photodynamic therapy versus Transpupillary thermotherapy
- Where
- Sweden
- Volunteers
- 140 people
- Sponsor
- St. Erik Eye Hospital
Subfoveal Choroidal Neovascularization
Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization
The purpose of this study is to compare the efficacy of photodynamic therapy with verteporfin (PDT) and IVTA vs triple therapy (TT) in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- NCT00930189
- Testing
- intravitreal injection of ranibizumab, intravitreal injection of triamcinolone, photodynamic therapy
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Asociación para Evitar la Ceguera en México
Corneal Neovascularisation
Strategies for Management of Corneal Neovascularisation
The cornea is the transparent window of the eye, which allows light to enter into the eye and also contributes to the focusing of the light rays.
- Trial name
- NCT02594423
- Testing
- Fine Needle Diathermy, Bevacizumab
- Volunteers
- 40 people
- Sponsor
- University of Nottingham
Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
- Trial name
- NCT04782271
- Testing
- SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique using a dual blade speculum among patients…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion With Macular Edema, Uveitic Macular Edema
- Trial name
- TIVI (NCT04455399)
- Testing
- Intravitreal injection guide (Malosa), Dual Blade Eyelid Speculum
- Where
- Philippines
- Volunteers
- 200 people
- Sponsor
- Peregrine Eye and Laser Institute
Presumed Ocular Histoplasmosis
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational…
- Trial name
- PLANE (NCT07695298)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cincinnati Eye Institute, Southwest Ohio
Pathological Myopia
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- NCT01217944
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 74 sites in Austria, Canada and 18 more
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV).
- Trial name
- POYANG (NCT06176352)
- Testing
- Faricimab, Ranibizumab
- Where
- 63 sites in Australia, China and 9 more
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Polypoidal Choroidal Vasculopathy
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy
- Trial name
- NCT03374670
- Testing
- Zimura, Eylea
- Where
- United States
- Sponsor
- Ophthotech Corporation